On January 22, 2026, the “Cengge Medicine 2026 Global Ecosystem Partner Alliance Conference and New Product Launch” was successfully held at the Marriott Hotel in Yangpu Binjiang, Shanghai. The conference brought together over 800 experts from the field of microecology, clinical professionals, industry pioneers, investors, and domestic and international partners. Liu Shuangjiang, President of the Gut Microbiota Branch of the Chinese Biophysical Society, Liu Hongwei, Director of the Microbiome Committee of the Chinese Microbiology Society, Qin Huanlong, Director of the Intestinal Microecology and Gut Microbioma Transplantation Committee of the China Health Technology Promotion Association, along with Frost & Sullivan, LeadLeo Research Institute, and other industry authorities, attended to discuss industrial development in depth. Wang Peng, Consultant Director of Frost & Sullivan’s Medical Health Division in China, was invited to speak.
Wang Peng, Consultant Director of Frost & Sullivan’s Medical Health Division in China
In his speech, Wang Peng pointed out that gut microbiota, as the “second genome” of the human body, are rapidly moving from early clinical exploration to industrialization and commercialization stages in drug development. In 2022 and 2023, the FDA approved two live biotherapeutic products for treating recurrent Clostridioides difficile infection, marking a significant breakthrough in clinical treatment of gut microbiota-related diseases and accelerating the industrialization of such drugs. In the future, these drugs are expected to reshape disease treatment patterns. Additionally, the global market is facing unprecedented opportunities, with potential breakthroughs in metabolic diseases, autoimmune diseases, and neurological disorders.
Wang Peng introduced REBYOTA®Approved by the FDA in November 2022, REBYOTA is used to prevent recurrent Clostridioides difficile infection in adults aged 18 and above after antibiotic treatment. It is the world’s first FDA-approved fecal microbiota transplantation live biotherapeutic product. Its key Phase III trial, PUNCH™ CD3®conducted using a randomized, double-blind, placebo-controlled design, combined with Bayesian statistical methods and Phase II study data. Results showed that the success rate for 8-week treatment in the REBYOTA group was 70.6%, significantly higher than 57.5% in the placebo group. Overall, it had good tolerability, and no serious treatment-related adverse events were reported, indicating clear efficacy and safety in reducing rCDI recurrence risk. Another drug, VOWST™, was approved in April 2023 for preventing rCDI and is the world’s first oral fecal microbiota transplantation alternative therapy. This multi-center randomized double-blind placebo-controlled trial showed that the three-day oral VOWST regimen significantly reduced the risk of rCDI recurrence, increasing the relapse-free rate to 87.6%, with good safety.
The gut microbiota market is currently driven by three core factors: first, growing market demand is a key driver. The incidence of inflammatory bowel disease, Clostridioides difficile infection, and other diseases is increasing due to lifestyle, antibiotic use, and aging trends, leading to a need for gut microbiota intervention technologies. The significant efficacy shown by existing drugs and therapies in clinical settings further expands market prospects. Second, capital investment is accelerating innovation, with increased global funding since 2019, especially in China where gut microbiota has become a focus of medical health investment. Third, policy support continues to generate benefits, with countries like China, the US, and the EU including gut microbiota research in national science and technology plans. Through special research funds and industry support policies, the industry is developing towards standardization and high quality. These three factors reinforce each other, driving rapid expansion and upgrading of the gut microbiota market.
Looking ahead, Wang Peng believes that the gut microbiota industry will continue to benefit from technological innovation, policy guidance, and improved payment systems. Frontier technologies such as synthetic biology, artificial intelligence-assisted strain design, and multi-omics integrated analysis will continue to improve drug development efficiency and expand indications.
